In clinical applications, 68Ga-labelled PSMA-targeting radioligands [7,8,9] are currently among the most frequently used due to the high number of patients suffering from prostate cancer, which may benefit from a PSMA-PET scan [10,11,12,13,14]. This evidence concerns the gene FOLH1 and prostate carcinoma.